logo image
search icon
Global Interferon Beta Drugs Market

Interferon Beta Drugs Market Size, Share & Trends Analysis Report By Product (Interferon Beta-1A, Interferon Beta-1B, Peginterferon Beta-1A), By Route of Administration (Intramuscular, Subcutaneous, Intravenous), By Distribution Channel, By Region, And By Segment Forecasts, 2024-2031

Report ID : 1282 | Published : 2024-05-23 | Pages: 180 | Format: PDF/EXCEL

The Interferon Beta Drugs Market Size is valued at USD 3.22 Billion in 2023 and is predicted to reach USD 4.66 Billion by the year 2031 at a 4.9 % CAGR during the forecast period for 2024-2031.

Key Industry Insights & Findings from the Report:

  • Government initiatives aimed at improving healthcare infrastructure, increasing awareness about M.S., and providing financial assistance for the treatment of chronic diseases contribute to the growth of the interferon beta drugs market.
  • Increasing healthcare expenditure, both in developed and under developing countries, enables patients to afford expensive treatments such as interferon beta drugs.
  • Europe region dominated the market & accounted for a global revenue share in 2023.
  • The high cost of treatment can act as a significant barrier to access, limiting market growth.

interferon drugs market

Interferon-beta (IFN) therapy has been used as a first-line or disease-modifying treatment for multiple sclerosis (MS). These drugs have been used to treat relapsing-remitting multiple sclerosis for the past 15 years (RRMS). A number of clinical trials and post-marketing studies have focused on the use of interferon beta drugs in slowing disease progression and even decreasing disease activity interferon—1b. Pharma companies have tested a variety of pharmacotherapies in the pursuit of developing the best treatment regimen for MS. This has broadened the clinical scope of new agents in the market for Interferon beta drugs. Several studies on the efficacy and safety of interferon beta (IFN) formulations on primary (or co-primary) endpoints have paved the way for drugs with good tolerability in relapsing-remitting MS. The increasing number of patients with secondary progressive MS has also fueled such research.

Moreover, the market for interferon beta (IFN) drugs has also seen new research directions as the prevalence of MS in women has increased. For instance, according to MST data from 2020, approximately 2,500,000 people worldwide have MS. According to scientists, the percentage of females with Multiple Sclerosis is increasing, and nearly 2 to 3 females have the disease. The prevalence of Multiple Sclerosis varies by region. According to the MTS, Asia, America, and Africa that rely on equatorial have a lower frequency of Multiple Sclerosis, whereas Canada and Scotland have a high frequency.

Competitive Landscape

Some Major Key Players In The Interferon Beta Drugs Market:

  • Biogen,
  • Merck,
  • Novartis,
  • Bayer,
  • Faron Pharmaceuticals,
  • other prominent players

Market Segmentation:

The global interferon beta drugs market is segmented on the basis of products, route of administration, and distribution channels. By-products, the market is segmented as interferon beta-1A, interferon beta-1B, and peginterferon beta-1A. The other route of administration segment includes intramuscular, subcutaneous, and intravenous. By distribution channels, the market is categorized into hospital pharmacies, retail pharmacies, and online pharmacies.

Based On Products, The Interferon-Beta-1A Segment Is Accounted As A Major Contributor To The Global Interferon Beta Drugs Market

Interferon-beta-1A drugs are used to treat multiple sclerosis (MS). Multiple sclerosis is a central nervous system disease that affects the brain and spinal cord. Communication issues between the brain and the rest of the body are common in people with multiple sclerosis. One of the factors driving the interferon market is the market's increasing emphasis on the development of novel interferon beta. For instance, Biogen Inc. received FDA approval in February 2021 for a new intramuscular (IM) injection route of administration for interferon (interferon beta-1a) for the treatment of relapsing forms of multiple sclerosis (MS). This novel intramuscular delivery of interferon provides people with relapsing multiple sclerosis with the drug's well-known efficacy and safety, as well as the possibility of significantly reduced injection site reactions.

The Hospital Pharmacies Segment Witnessed Growth At A Rapid Rate

In 2020, the Hospital Pharmacies had the highest market share by distribution channel segment. The initiatives of market participants in this segment are expected to boost market growth. The ongoing efforts of major players to develop advanced medication for the effective treatment of diseases contribute to the market share.

In The Region, The Europe Interferon Beta Drugs Market Holds A Significant Revenue Share.

The presence of major players, interferon beta drug approval, and the increasing prevalence of MS in the region are expected to drive significant growth in the Europe interferon beta drugs market during the forecast period. For instance, in 2019, the Russian Ministry of Health approved BIOCAD, a Russian biotechnology company, for BCD-033, an interferon beta-1a non-originator biological drug. The medication is a biological non-originator of Merck's blockbuster multiple sclerosis drug Rebif (interferon beta-1a). Moreover, the presence of major players in Europe, such as Bayar, Novartis, and Merck KGaA, contributes to the growth of the Europe interferon beta drugs market. On the other hand, North America is also expected to dominate the interferon market due to its citizens' increased awareness of such advanced treatment therapies, as well as the region's developed medical and healthcare establishment and availability of experts. There were approximately 3,200 cases of hepatitis B in the U.S. in 2019, with Florida accounting for 595 patients, making it the state with the most hepatitis B infections in the country. The mortality rate for Hepatitis B is low; however, males die slightly higher than females. As a result, the demand for interferons will be significantly higher in the North American region as the patient population grows faster than in other countries.

Recent Developments:

  • In Feb 2021, Biogen Inc declared that PLEGRIDY® (peginterferon beta-1a) may now be administered via an additional intramuscular (I.M.) injection method by the U.S. Food & Drug Administration (FDA) for the treatment of relapse types of multiple sclerosis (M.S.).

Interferon Beta Drugs Market Report Scope

Report Attribute

Specifications

Market size value in 2023

USD 3.22 Billion

Revenue forecast in 2031

USD 4.66 Billion

Growth rate CAGR

CAGR of 4.9 % from 2024 to 2031

Quantitative units

Representation of revenue in US$ Billion and CAGR from 2024 to 2031

Historic Year

2019 to 2023

Forecast Year

2024-2031

Report coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments covered

By Products, Route of Administration, Distribution Channel

Regional scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia

Competitive Landscape

Biogen, Merck, Novartis, Bayer, Faron Pharmaceuticals, and other prominent players

Customization scope

Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape.

Pricing and available payment methods

Explore pricing alternatives that are customized to your particular study requirements.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Interferon Beta Drugs Market Snapshot

Chapter 4. Global Interferon Beta Drugs Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Penetration & Growth Prospect Mapping

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. By Products Advancement in Ambulatory Mammography

Chapter 5. Market Segmentation 1: By Products Estimates & Trend Analysis

5.1. By Products & Market Share, 2019 & 2031

5.2. Market Size (Value) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Products:

5.2.1. Interferon Beta-1A

5.2.2. Interferon Beta-1B

5.2.3. Peginterferon Beta-1A

Chapter 6. Market Segmentation 1: By Route of Administrations & Trend Analysis

6.1. By Route of Administrations & Market Share, 2019 & 2031

6.2. Market Size (Value)& Forecasts and Trend Analyses, 2019 to 2031 for the following By Route of Administrations:

6.2.1. Intramuscular

6.2.2. Subcutaneous

6.2.3. Intravenous

Chapter 7. Market Segmentation 1: By Distribution Channels & Trend Analysis

7.1. By Distribution Channels & Market Share, 2019 & 2031

7.2. Market Size (Value)& Forecasts and Trend Analyses, 2019 to 2031 for the following By Distribution Channels

7.2.1. Hospital Pharmacies

7.2.2. Retail Pharmacies

7.2.3. Online Pharmacies

Chapter 8. Interferon Beta Drugs Market Segmentation 3: Regional Estimates & Trend Analysis

8.1. North America

8.1.1. North America Interferon Beta Drugs Market revenue (US$ Million) estimates and forecasts By Products, 2024-2031

8.1.2. North America Interferon Beta Drugs Market revenue (US$ Million) estimates and forecasts By Route of Administrations, 2024-2031

8.1.3. North America Interferon Beta Drugs Market revenue (US$ Million) estimates and forecasts By Distribution Channels, 2024-2031

8.1.4. North America Interferon Beta Drugs Market revenue (US$ Million) estimates and forecasts by country, 2024-2031

8.1.4.1. U.S.

8.1.4.2. Canada

8.2. Europe

8.2.1. Europe Interferon Beta Drugs Market revenue (US$ Million) By Products, 2024-2031

8.2.2. Europe Interferon Beta Drugs Market revenue (US$ Million) estimates and forecasts By Route of Administrations, 2024-2031

8.2.3. Europe Interferon Beta Drugs Market revenue (US$ Million) estimates and forecasts By Distribution Channels, 2024-2031

8.2.4. Europe Interferon Beta Drugs Market revenue (US$ Million) by country, 2024-2031

8.2.4.1. Germany

8.2.4.2. Poland

8.2.4.3. France

8.2.4.4. Italy

8.2.4.5. Spain

8.2.4.6. UK

8.2.4.7. Rest of Europe 

8.3. Asia Pacific

8.3.1. Asia Pacific Interferon Beta Drugs Market revenue (US$ Million) By Products, 2024-2031

8.3.2. Asia Pacific Interferon Beta Drugs Market revenue (US$ Million) estimates and forecasts By Route of Administrations, 2024-2031

8.3.3. Asia Pacific Interferon Beta Drugs Market revenue (US$ Million) estimates and forecasts By Distribution Channels, 2024-2031

8.3.4. Asia Pacific Interferon Beta Drugs Market revenue (US$ Million) by country, 2024-2031

8.3.4.1. China

8.3.4.2. India

8.3.4.3. Japan

8.3.4.4. Australia

8.3.4.5. Rest of Asia Pacific

8.4. Latin America

8.4.1. Latin America Interferon Beta Drugs Market revenue (US$ Million) By Products, 2024-2031

8.4.2. Latin America Interferon Beta Drugs Market revenue (US$ Million) estimates and forecasts By Route of Administrations, 2024-2031

8.4.3. Latin America Interferon Beta Drugs Market revenue (US$ Million) estimates and forecasts By Distribution Channels, 2024-2031

8.4.4. Latin America Interferon Beta Drugs Market revenue (US$ Million) by country, 2024-2031

8.4.4.1. Brazil

8.4.4.2. Rest of Latin America

8.5. MEA

8.5.1. MEA Interferon Beta Drugs Market revenue (US$ Million) estimates and forecasts By Products, 2024-2031

8.5.2. MEA Interferon Beta Drugs Market revenue (US$ Million) estimates and forecasts By Route of Administrations, 2024-2031

8.5.3. MEA Interferon Beta Drugs Market revenue (US$ Million) estimates and forecasts By Distribution Channels, 2024-2031

8.5.4. MEA revenue Interferon Beta Drugs Market revenue (US$ Million) by country, (US$ Million) 2024-2031

8.5.4.1. South Africa

8.5.4.2. Rest of MEA 

Chapter 9. Competitive Landscape

9.1. Major Mergers and Acquisitions/Strategic Alliances

9.2. Company Profiles

9.2.1. Biogen

9.2.2. Merck

9.2.3. Novartis

9.2.4. Bayer

9.2.5. Faron Pharmaceuticals

Other Prominent Players

Segmentation of Global Interferon Beta Drugs Market -

Global Interferon Beta Drugs Market By Products -

  • Interferon Beta-1A
  • Interferon Beta-1B
  • Peginterferon Beta-1A

interferon beta drugs

Global Interferon Beta Drugs Market By Route of Administrations -

  • Intramuscular
  • Subcutaneous
  • Intravenous

Global Interferon Beta Drugs Market By Distribution Channels -

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Global Interferon Beta Drugs Market By Region -

North America -

  • The U.S.
  • Canada
  • Mexico

Europe -

  • Germany
  • The U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific -

  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific

Latin America -

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa -

  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

user icon
office icon
mail icon
call icon

This website is secure, and we do not share your personal information with any third party. Privacy Policy

Need Customization
Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Frequently Asked Questions

Who are the Key Players in the Interferon Beta Drugs Market?

The Interferon Beta Drugs Market Size is valued at USD 3.22 Billion in 2023 and is predicted to reach USD 4.66 Billion by the year 2031

The Interferon Beta Drugs Market is expected to grow at an 4.9 % CAGR during the forecast period for 2024-2031.

Our Clients

  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo

Media Citations

  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo

Growth opportunities and latent adjacency in Pharmaceuticals

Select Licence Type
$4456
$7786
$10000
$1200
Get Your GTM Strategy

Navigate market entry with channel selection, launch strategy & timeline, and pricing model support.

Equip yourself with the insights needed to develop a winning go-to-market strategy

Get real-time updates and joint control over project direction with our collaborative approach